A STUDY OF END TYROSINE KINASE INHIBITOR IN CML (ENTIC) IN MALAYSIA

被引：0

作者：

Chong, SiewLian ^{[1
]}

Asnawi, Asral Wirda Ahmad ^{[1
,2
]}

Wong, Tien Gen ^{[1
]}

Selvaratnam, Veena ^{[1
]}

Liew, Pek Kuen ^{[1
]}

Abd Kadir, Sharifah Shahnaz Syed ^{[1
]}

Ong, Tee Chuan ^{[1
]}

Tan, Jerome ^{[1
]}

Lau, Ngee Siang ^{[1
]}

Tan, Sen Mui ^{[1
]}

Goh, Ai Sim ^{[3
]}

Lim, Soo Min ^{[4
]}

Kori, Ahlam Naila ^{[5
]}

Toh, See Guan ^{[6
]}

Ng, Si Yuan ^{[7
]}

Tan, Jenq Tzong ^{[8
]}

机构：

[1] Hosp Ampang Ampang, Ampang, Malaysia

[2] Univ Sains Islam Malaysia Bandar Baru Nilai, Fac Med & Hlth Sci, Nilai, Negeri Sembilan, Malaysia

[3] Hosp Pulau Pinang Penang, George Town, Malaysia

[4] Hosp Sultanah Aminah Johor Bahru, Johor Baharu, Malaysia

[5] Hosp Tengku Ampuan Afzan Kuantan, Pahang, Malaysia

[6] Hosp Tuanku Jaafar Seremban, Seremban, Malaysia

[7] Hosp Melaka, Melaka, Malaysia

[8] Hosp Taiping Perak, Taiping, Malaysia

来源：

INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY | 2023年 / 45卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：23 / 23

页数：1

共 50 条

[1] A Real-World Study to End Tyrosine Kinase Inhibitor in Chronic Myeloid Leukaemia (EnTIC) in Malaysia: One Year Follow-up of Multicenter Study in Malaysia
Chong, SiewLian
Ong, Tee Chuan
Asnawi, Wirda
Wong, Tien Gen
Zakiyy, Mohamed Ahmad
Tham, Yea Bing
Shuyuti, Nur Aini Syakirah Ahmad
Abd Kadir, Sharifah Shahnaz Binti Syed
Tan, Jerome
Ho, Kim Wah
Lau, Ngee Siang
Yee, Yap Yee
Selvaratnam, Veena
Tan, Sen Mui
Goh, Ai Sim
Teoh, Ching Soon
Keat, Sui
Lim, Soo Min
Sharif, Azizan
Boo, Yang Liang
Liam, Christopher
Kori, Ahlam Naila
Toh, See Guan
Gan, Ee Leng
Ng, Si Yuan
Hon, Siong Leng
Tan, Jenq Tzong
BLOOD, 2022, 140 : 12213 - 12214
[2] Cardiovascular Toxicities of Tyrosine Kinase Inhibitor in CML
Master, Samip R.
Mansour, Richard Preston
BLOOD, 2020, 136
[3] Tyrosine kinase inhibitor for CML: all the same?
Veltmaat, Lukas
Cortes, Jorge
BLOOD ADVANCES, 2024, 8 (20) : 5339 - 5341
[4] CHOICE OF FRONTLINE TYROSINE KINASE INHIBITOR IN VERY ELDERLY CML PATIENTS: A "CAMPUS CML" STUDY
Latagliata, R.
Capodanno, I.
Miggiano, M. C.
Bucelli, C.
Cavazzini, F.
Crescenzi, S. Leonetti
Russo, S.
Colafigli, G.
Annunziata, M.
Sora, F.
Bonifacio, M.
Luciano, L.
Caocci, G.
Loglisci, G.
Elena, C.
Mullai, R.
Attolico, I.
Binotto, G.
Crisa, E.
Iurlo, A.
Sportoletti, P.
Di Veroli, A.
Scortechini, A. R.
Leporace, A. P.
Maggi, A.
Crugnola, M.
Stagno, F.
Sancetta, R.
Murgano, P.
Rapezzi, D.
Luzi, D.
Bocchia, M.
Fava, C.
Saglio, G.
Specchia, G.
Breccia, M.
Tiribelli, M.
HAEMATOLOGICA, 2021, 106 (10) : 101 - 102
[5] Predicting the Response of CML Patients to Tyrosine Kinase Inhibitor Therapy
White, Deborah L.
Hughes, Timothy P.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2011, 6 (02) : 88 - 95
[6] Predicting the Response of CML Patients to Tyrosine Kinase Inhibitor Therapy
Deborah L. White
Timothy P. Hughes
Current Hematologic Malignancy Reports, 2011, 6
[7] Predicting the response of CML patients to tyrosine kinase inhibitor therapy
White D.L.
Hughes T.P.
Current Hematologic Malignancy Reports, 2009, 4 (2) : 59 - 65
[8] A CML case with resistant pleural effusion with tyrosine kinase inhibitor treatment
Malkan, Umit Yavuz
Haznedaroglu, Ibrahim Celalettin
INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2016, 9 (07): : 14884 - 14887
[9] Tyrosine Kinase Inhibitor Responses in Pediatric CML Patients: Hacettepe Experience
Bajin, I. Yaman
Aytac, S.
Kuskonmaz, B.
Unal, S.
Okur, V.
Cetinkaya, D.
Cetin, M.
Gumruk, F.
PEDIATRIC BLOOD & CANCER, 2017, 64 : S202 - S202
[10] Combination of an aurora kinase inhibitor and the ABL tyrosine kinase inhibitor asciminib against ABL inhibitor-resistant CML cells
Okabe, Seiichi
Moriyama, Mitsuru
Gotoh, Akihiko
MEDICAL ONCOLOGY, 2024, 41 (06)

← 1 2 3 4 5 →